

Europe



**IABS-EU OFFICE**

World Trade Center  
Tour Oxygène  
Boulevard Vivier Merle  
69393 Lyon  
Cedex 03  
FRANCE

**CONTACT OUR TEAM:**

**Dr. Joris Vandeputte**  
Executive Director, IABS  
Chairman, IABS-EU  
Tel: +32 (0) 65 75 52 85  
Cell: +32 (0) 473 52 83 92  
Email: [joris.vandeputte@iabs.org](mailto:joris.vandeputte@iabs.org)

**Abigail Charlet**  
Director IABS-EU Office  
Tel: +33 (0) 4 26 02 18 10  
Cell: +33 (0) 688 07 18 24  
Email: [abbie.charlet@iabs.org](mailto:abbie.charlet@iabs.org)

**Dr. Johan Vanhemelrijck**  
Advisor  
Tel: + 32 (0) 2 706 81 77  
Cell: +32 (0) 475 30 62 57  
Email: [johan.vanhemelrijck@iabs.org](mailto:johan.vanhemelrijck@iabs.org)

[www.iabs.org](http://www.iabs.org)

Europe



**International Alliance for Biological Standardization**

*Your essential partner in support of EU  
projects focused on innovative research  
and development of biologicals  
from vaccines up to cells and tissues*

DISSEMINATION OF RESEARCH RESULTS

BRIDGE BETWEEN PUBLIC AND  
PRIVATE SECTORS

MORE THAN 130  
INTERNATIONAL CONFERENCES  
ORGANISED TO DATE

BUILDING CONSENSUS ACROSS  
STAKEHOLDER SPECTRUM

SCIENTIFIC JOURNAL  
"BIOLOGICALS"

Europe



## International Alliance for Biological Standardization

IABS is an essential partner in support of biological research projects on innovative research and development of biologicals from vaccines up to cells and tissues.

IABS can be a reliable and decisive partner in projects involving biologicals by its ability to pool worldwide expertise on biological standardisation, an essential and integral part of early development.

Moreover, IABS, through the organisation of international conferences, involves the biological communities of regulatory authorities, industry and academia as essential partners in building consensus on norms and standards, and dissemination of their availability at the international level.

The International Alliance for Biological Standardization (IABS), located in Geneva, Switzerland, and in Lyon, France as *IABS-EU*, is a non-profit association recognized as an NGO by the World Health Organization. The mission of IABS is to contribute to the scientific and medical advancement of biologicals by facilitating communication among those who develop, produce and regulate biological products for human and animal health.

### MARK THE UPCOMING IABS CONFERENCES AND WORKSHOPS IN YOUR CALENDAR:

- *Statistical and Data Management Approaches for Biotechnology Drug Development*  
August 27 - 28, 2014 - USP Meeting Center, Rockville, Maryland
- *Human Challenge Trials in Vaccine Development: Scientific and Regulatory Issues*  
September 29 - October 1, 2014 - EDQM, Strasbourg, France

A unique feature of IABS is that it acts as a neutral meeting point for the major stakeholders - regulators, academia, and industry- to consider the impact of regulatory requirements on innovation, with the objective of identifying sections that may require modification. IABS realizes this overall objective as follows:

- IABS brings together an outstanding and diverse group of experts, from regulatory agencies, industry, academia, all of whom are at the forefront of biologicals research and development, including the cell therapy field.
- IABS increases awareness of the diverse views of global stakeholders.
- IABS initiates, organises and promotes continued international dialogue and exchange of information and points of view in the evolving field of biologicals.
- IABS generates a common international recognition of the essential scientific elements for research and early product development, evaluation and control of biologicals including cell therapy products.
- IABS identifies very critical points/issues to be resolved, improved, and/or developed in terms of science-based regulation in order to facilitate the availability of products globally important to public health in a rational and timely manner.
- IABS publishes the scientific journal *BIOLOGICALS* as an essential dissemination tool for research and information in this field.
- IABS facilitates decision-making based on helping to ensure an efficient standard-setting basis in the regulatory approval process. Including IABS as a partner is therefore critically important also for early research projects.
- IABS is especially interested in improving the predictability of early efficacy and safety research on biological products. This is in line with efforts to reduce late fallout and costs of phase 3 clinical trials.
- Please visit our website at <http://www.iabs.org> to find out if, how and with whom IABS could be a potential partner in EU research projects.